Malaysia-based medical technology company Haemonetics has received the US Food and Drug Administration (FDA) approval for enhancements to its NexSys PCS plasma collection system.
The enhancements include a new plasma collection bowl that features a patented design, and new Express Plus Technology, which is engineered to reduce procedure time.
NexSys PCS is an advanced, completely integrated system designed to simplify plasma collections and improve productivity, safety, quality, compliance and donor satisfaction.
Bi-directionally connected with NexLynk DMS donor management software, NexSys PCS reduces average donor door-to-door time by 16 minutes.
When used together with Persona Technology, the system safely delivers around 9% to 12% additional plasma yield, by personalising each collection to individual donor characteristics.
Haemonetics intends to initially commercialise the NexSys PCS system, with the new bowl and Express Plus Technology, in the coming months.
Haemonetics global plasma and blood centre president Roy Galvin said: “Haemonetics sets the standard in global plasma collection solutions that meet collectors’ most critical needs.
“With our redesigned bowl and new Express Plus Technology for faster procedure times and enhanced plasma centre efficiency, we continue to advance our innovation to lead the industry in reducing cost per litre for collectors and ensuring the best experience for their donors.”
Haemonetics is a global healthcare company engaged in providing advanced medical products and solutions to help improve patient care and reduce the cost of healthcare.
The company has five decades of experience in the plasma collections market and has carried out more than 50 million real-world collections on NexSys PCS to date.
Its technology addresses key medical markets such as blood and plasma component collection, the surgical suite and hospital transfusion services, said the company.
